A clinical appraisal of pentapyrrolidinium (M&B 2050) in hypertensive patients.

The new ganglionic blocking agent, pentnpyrrolidinium or M&B 2050, appears to have several distinct advantages over hesamethonium in the treatment of severe hypertension. These advantages include longer duration of action, greater potency, less tolerance, less interference with intestinal motility, and, most important, a more uniform response from day to day on oral :&ninistration. However, critical adjustment of dosage is necessary and side effects are not infrequent, the most disturbing being post’ural faintness and impotence.